Epidemiology and Inherited Predisposition for Sporadic Pancreatic Adenocarcinoma

Hematology/Oncology Clinics of North America

Volumn 29, Issue 4, 2015, Pages 619-640

  Stolzenberg Solomon, Rachael Z ^a   Amundadottir, Laufey T ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Diabetes; Etiology; Genome wide association studies; Pancreatic cancer

Indexed keywords

FRUCTOSE; METFORMIN; ORAL ANTIDIABETIC AGENT; SATURATED FATTY ACID;

ALCOHOL CONSUMPTION; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CHINESE; COFFEE; DIABETES MELLITUS; DISEASE ASSOCIATION; FAMILIAL CANCER; FAT INTAKE; GENE MAPPING; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETIC SUSCEPTIBILITY; HIGH THROUGHPUT SEQUENCING; HUMAN; INSULIN RESISTANCE; JAPANESE (PEOPLE); NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PANCREAS ADENOCARCINOMA; PANCREATITIS; PRIORITY JOURNAL; RED MEAT; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TOBACCO USE; TYPE 3C DIABETES; ADENOCARCINOMA; ANIMAL; GENETICS; GENOME-WIDE ASSOCIATION STUDY; INCIDENCE; PANCREATIC NEOPLASMS; RISK FACTOR; UNITED STATES;

ADENOCARCINOMA; ANIMALS; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; INCIDENCE; PANCREATIC NEOPLASMS; RISK FACTORS; UNITED STATES;

EID: 84938062691     PISSN: 08898588     EISSN: 15581977     Source Type: Journal    
DOI: 10.1016/j.hoc.2015.04.009     Document Type: Review

References (156)

1. Ferlay J., Soerjomataram I., Dikshit R., et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015, 136(5):E359-E386.
2. Edwards B.K., Noone A.M., Mariotto A.B., et al. Annual Report to the Nation on the status of cancer, 1975-2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer. Cancer 2014, 120:1290-1314.
3. SEER Stat fact sheets: pancreatic cancer. In: Surveillance, epidemiology, and end results program. 2014.
4. Anderson K.E., Mack T.M., Silverman D.T. Cancer of the pancreas. Cancer epidemiology and prevention 2006, 721-763. Oxford University Press, New York. 3rd edition. D. Schottenfeld, J.F. Fraumeni (Eds.).
5. A snapshot of pancreatic cancer. 2014. Available at: . http://www.cancer.gov/research/progress/snapshots/pancreatic.
6. Rahib L., Smith B.D., Aizenberg R., et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res 2014, 74:2913-2921.
7. Ben Q., Xu M., Ning X., et al. Diabetes mellitus and risk of pancreatic cancer: a meta-analysis of cohort studies. Eur J Cancer 2011, 47:1928-1937.
8. Huxley R., Ansary-Moghaddam A., Berrington D.G., et al. Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer 2005, 92:2076-2083.
9. Bosetti C., Rosato V., Li D., et al. Diabetes, antidiabetic medications, and pancreatic cancer risk: an analysis from the International Pancreatic Cancer Case-Control Consortium. Ann Oncol 2014, 25:2065-2072.
10. Grote V.A., Rohrmann S., Nieters A., et al. Diabetes mellitus, glycated haemoglobin and C-peptide levels in relation to pancreatic cancer risk: a study within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. Diabetologia 2011, 54:3037-3046.
11. Wolpin B.M., Bao Y., Qian Z.R., et al. Hyperglycemia, insulin resistance, impaired pancreatic beta-cell function, and risk of pancreatic cancer. J Natl Cancer Inst 2013, 105:1027-1035.
12. Stolzenberg-Solomon R.Z., Graubard B.I., Chari S., et al. Insulin, glucose, insulin resistance, and pancreatic cancer in male smokers. JAMA 2005, 294:2872-2878.
13. Douglas J.B., Silverman D.T., Pollak M.N., et al. Serum IGF-I, IGF-II, IGFBP-3, and IGF-I/IGFBP-3 molar ratio and risk of pancreatic cancer in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Epidemiol Biomarkers Prev 2010, 19:2298-2306.
14. Douglas J.B., Silverman D.T., Weinstein S.J., et al. Serum C-reactive protein and risk of pancreatic cancer in two nested, case-control studies. Cancer Epidemiol Biomarkers Prev 2011, 20:359-369.
15. Jiao L., Weinstein S.J., Albanes D., et al. Evidence that serum levels of the soluble receptor for advanced glycation end products are inversely associated with pancreatic cancer risk: a prospective study. Cancer Res 2011, 71:3582-3589.
16. Grote V.A., Nieters A., Kaaks R., et al. The associations of advanced glycation end products and its soluble receptor with pancreatic cancer risk: a case-control study within the prospective EPIC Cohort. Cancer Epidemiol Biomarkers Prev 2012, 21:619-628.
17. Grote V.A., Rohrmann S., Dossus L., et al. The association of circulating adiponectin levels with pancreatic cancer risk: a study within the prospective EPIC cohort. Int J Cancer 2012, 130:2428-2437.
18. Kaaks R., Lukanova A. Energy balance and cancer: the role of insulin and insulin-like growth factor-I. Proc Nutr Soc 2001, 60:91-106.
19. Mayers J.R., Wu C., Clish C.B., et al. Elevation of circulating branched-chain amino acids is an early event in human pancreatic adenocarcinoma development. Nat Med 2014, 20:1193-1198.
20. Newgard C.B., An J., Bain J.R., et al. A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. Cell Metab 2009, 9:311-326.
21. Duell E.J., Lucenteforte E., Olson S.H., et al. Pancreatitis and pancreatic cancer risk: a pooled analysis in the International Pancreatic Cancer Case-Control Consortium (PanC4). Ann Oncol 2012, 23:2964-2970.
22. Lowenfels A.B., Maisonneuve P., Cavallini G., et al. Pancreatitis and the risk of pancreatic cancer. International Pancreatitis Study Group. N Engl J Med 1993, 328:1433-1437.
23. Ewald N., Kaufmann C., Raspe A., et al. Prevalence of diabetes mellitus secondary to pancreatic diseases (type 3c). Diabetes Metab Res Rev 2012, 28:338-342.
24. Andersen D.K. The practical importance of recognizing pancreatogenic or type 3c diabetes. Diabetes Metab Res Rev 2012, 28:326-328.
25. National Diabetes Information Clearinghouse Monogenic forms of diabetes: neonatal diabetes mellitus and maturity-onset diabetes of the young 2014, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Institutes of Health, Department of Health and Human Services.
26. Pierce B.L., Ahsan H. Genome-wide "pleiotropy scan" identifies HNF1A region as a novel pancreatic cancer susceptibility locus. Cancer Res 2011, 71:4352-4358.
27. Li D., Duell E.J., Yu K., et al. Pathway analysis of genome-wide association study data highlights pancreatic development genes as susceptibility factors for pancreatic cancer. Carcinogenesis 2012, 33:1384-1390.
28. Wolpin B.M., Rizzato C., Kraft P., et al. Genome-wide association study identifies multiple susceptibility loci for pancreatic cancer. Nat Genet 2014, 46:994-1000.
29. Maestro M.A., Cardalda C., Boj S.F., et al. Distinct roles of HNF1beta, HNF1alpha, and HNF4alpha in regulating pancreas development, beta-cell function and growth. Endocr Dev 2007, 12:33-45.
30. Martin M., Hauer V., Messmer M., et al. Transcription factors in pancreatic development. Animal models. Endocr Dev 2007, 12:24-32.
31. Bodmer M., Becker C., Meier C., et al. Use of antidiabetic agents and the risk of pancreatic cancer: a case-control analysis. Am J Gastroenterol 2012, 107(4):620-626.
32. Gandini S., Puntoni M., Heckman-Stoddard B.M., et al. Metformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders. Cancer Prev Res (Phila) 2014, 7:867-885.
33. Lynch S.M., Vrieling A., Lubin J.H., et al. Cigarette smoking and pancreatic cancer: a pooled analysis from the Pancreatic Cancer Cohort Consortium. Am J Epidemiol 2009, 170:403-413.
34. Bertuccio P., La V.C., Silverman D.T., et al. Cigar and pipe smoking, smokeless tobacco use and pancreatic cancer: an analysis from the International Pancreatic Cancer Case-Control Consortium (PanC4). Ann Oncol 2011, 22:1420-1426.
35. Maisonneuve P., Lowenfels A.B. Risk factors for pancreatic cancer: a summary review of meta-analytical studies. Int J Epidemiol 2015, 44(1):186-198.
36. Genkinger J.M., Spiegelman D., Anderson K.E., et al. A pooled analysis of 14 cohort studies of anthropometric factors and pancreatic cancer risk. Int J Cancer 2011, 129:1708-1717.
37. Aune D., Greenwood D.C., Chan D.S., et al. Body mass index, abdominal fatness and pancreatic cancer risk: a systematic review and non-linear dose-response meta-analysis of prospective studies. Ann Oncol 2012, 23:843-852.
38. Eberle C.A., Bracci P.M., Holly E.A. Anthropometric factors and pancreatic cancer in a population-based case-control study in the San Francisco Bay Area. Cancer Causes Control 2005, 16:1235-1244.
39. Fryzek J.P., Schenk M., Kinnard M., et al. The association of body mass index and pancreatic cancer in residents of southeastern Michigan, 1996-1999. Am J Epidemiol 2005, 162:222-228.
40. Li D., Morris J.S., Liu J., et al. Body mass index and risk, age of onset, and survival in patients with pancreatic cancer. JAMA 2009, 301:2553-2562.
41. Ji B.T., Hatch M.C., Chow W.H., et al. Anthropometric and reproductive factors and the risk of pancreatic cancer: a case-control study in Shanghai, China. Int J Cancer 1996, 66:432-437.
42. Urayama K.Y., Holcatova I., Janout V., et al. Body mass index and body size in early adulthood and risk of pancreatic cancer in a central European multicenter case-control study. Int J Cancer 2011, 129:2875-2884.
43. Patel A.V., Rodriguez C., Bernstein L., et al. Obesity, recreational physical activity, and risk of pancreatic cancer in a large U.S. cohort. Cancer Epidemiol Biomarkers Prev 2005, 14:459-466.
44. Michaud D.S., Giovannucci E., Willett W.C., et al. Physical activity, obesity, height, and the risk of pancreatic cancer. JAMA 2001, 286:921-929.
45. Levi Z., Kark J.D., Afek A., et al. Measured body mass index in adolescence and the incidence of pancreatic cancer in a cohort of 720,000 Jewish men. Cancer Causes Control 2012, 23:371-378.
46. Stolzenberg-Solomon R.Z., Schairer C., Moore S., et al. Lifetime adiposity and risk of pancreatic cancer in the NIH-AARP Diet and Health Study cohort. Am J Clin Nutr 2013, 98:1057-1065.
47. World Cancer Research Fund and American Institute for Cancer Research. Continuous update project summary. Food, nutrition, physical activity, and the prevention of pancreatic cancer. 2012. Available at: . http://www.dietandcancerreport.org.
48. Arem H., Reedy J., Sampson J., et al. The healthy eating index 2005 and risk of pancreatic cancer in the NIH-AARP Study. J Natl Cancer Inst 2013, 105(17):1298-1305.
49. Jiao L., Mitrou P.N., Reedy J., et al. A combined healthy lifestyle score and risk of pancreatic cancer in a large cohort study. Arch Invest Med 2009, 169:764-770.
50. Bosetti C., Bravi F., Turati F., et al. Nutrient-based dietary patterns and pancreatic cancer risk. Ann Epidemiol 2013, 23:124-128.
51. Chan J.M., Gong Z., Holly E.A., et al. Dietary patterns and risk of pancreatic cancer in a large population-based case-control study in the San Francisco Bay Area. Nutr Cancer 2013, 65:157-164.
52. Jiao L., Silverman D.T., Schairer C., et al. Alcohol use and risk of pancreatic cancer: the NIH-AARP Diet and Health Study. Am J Epidemiol 2009, 169:1043-1051.
53. Gapstur S.M., Jacobs E.J., Deka A., et al. Association of alcohol intake with pancreatic cancer mortality in never smokers. Arch Invest Med 2011, 171:444-451.
54. Lucenteforte E., La V.C., Silverman D., et al. Alcohol consumption and pancreatic cancer: a pooled analysis in the International Pancreatic Cancer Case-Control Consortium (PanC4). Ann Oncol 2012, 23:374-382.
55. Genkinger J.M., Spiegelman D., Anderson K.E., et al. Alcohol intake and pancreatic cancer risk: a pooled analysis of fourteen cohort studies. Cancer Epidemiol Biomarkers Prev 2009, 18:765-776.
56. Stolzenberg-Solomon R.Z., Vieth R., Azad A., et al. A prospective nested case-control study of vitamin D status and pancreatic cancer risk in male smokers. Cancer Res 2006, 66:10213-10219.
57. Stolzenberg-Solomon R.Z., Hayes R.B., Horst R.L., et al. Serum vitamin D and risk of pancreatic cancer in the prostate, lung, colorectal, and ovarian screening trial. Cancer Res 2009, 69:1439-1447.
58. Stolzenberg-Solomon R.Z., Jacobs E.J., Arslan A.A., et al. Circulating 25-hydroxyvitamin D and risk of pancreatic cancer: Cohort Consortium Vitamin D Pooling Project of Rarer Cancers. Am J Epidemiol 2010, 172:81-93.
59. Wolpin B.M., Ng K., Bao Y., et al. Plasma 25-hydroxyvitamin D and risk of pancreatic cancer. Cancer Epidemiol Biomarkers Prev 2012, 21(1):82-91.
60. Amundadottir L., Kraft P., Stolzenberg-Solomon R.Z., et al. Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. Nat Genet 2009, 41:986-990.
61. Petersen G.M., Amundadottir L., Fuchs C.S., et al. A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33. Nat Genet 2010, 42:224-228.
62. Campa D., Rizzato C., Capurso G., et al. Genetic susceptibility to pancreatic cancer and its functional characterisation: the PANcreatic Disease ReseArch (PANDoRA) consortium. Dig Liver Dis 2013, 45:95-99.
63. Marcus D.M. The ABO and Lewis blood-group system. Immunochemistry, genetics and relation to human disease. N Engl J Med 1969, 280:994-1006.
64. Aird I., Bentall H.H., Roberts J.A. A relationship between cancer of stomach and the ABO blood groups. Br Med J 1953, 1:799-801.
65. Wolpin B.M., Kraft P., Gross M., et al. Pancreatic cancer risk and ABO blood group alleles: results from the Pancreatic Cancer Cohort Consortium. Cancer Res 2010, 70:1015-1023.
66. Wolpin B.M., Kraft P., Xu M., et al. Variant ABO blood group alleles, secretor status, and risk of pancreatic cancer: results from the Pancreatic Cancer Cohort Consortium. Cancer Epidemiol Biomarkers Prev 2010, 19:3140-3149.
67. Yamamoto F., McNeill P.D., Hakomori S. Human histo-blood group A2 transferase coded by A2 allele, one of the A subtypes, is characterized by a single base deletion in the coding sequence, which results in an additional domain at the carboxyl terminal. Biochem Biophys Res Commun 1992, 187:366-374.
68. Zhang B.L., He N., Huang Y.B., et al. ABO blood groups and risk of cancer: a systematic review and meta-analysis. Asian Pac J Cancer Prev 2014, 15:4643-4650.
69. Franchini M., Liumbruno G.M. ABO blood group: old dogma, new perspectives. Clin Chem Lab Med 2013, 51:1545-1553.
70. Khalili H., Wolpin B.M., Huang E.S., et al. ABO blood group and risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev 2011, 20:1017-1020.
71. Gates M.A., Wolpin B.M., Cramer D.W., et al. ABO blood group and incidence of epithelial ovarian cancer. Int J Cancer 2011, 128:482-486.
72. Fayard E., Auwerx J., Schoonjans K. LRH-1: an orphan nuclear receptor involved in development, metabolism and steroidogenesis. Trends Cell Biol 2004, 14:250-260.
73. Kelly V.R., Xu B., Kuick R., et al. Dax1 up-regulates Oct4 expression in mouse embryonic stem cells via LRH-1 and SRA. Mol Endocrinol 2010, 24:2281-2291.
74. Heng J.C., Feng B., Han J., et al. The nuclear receptor Nr5a2 can replace Oct4 in the reprogramming of murine somatic cells to pluripotent cells. Cell Stem Cell 2010, 6:167-174.
75. Holmstrom S.R., Deering T., Swift G.H., et al. LRH-1 and PTF1-L coregulate an exocrine pancreas-specific transcriptional network for digestive function. Genes Dev 2011, 25:1674-1679.
76. Pare J.F., Malenfant D., Courtemanche C., et al. The fetoprotein transcription factor (FTF) gene is essential to embryogenesis and cholesterol homeostasis and is regulated by a DR4 element. J Biol Chem 2004, 279:21206-21216.
77. Flandez M., Cendrowski J., Canamero M., et al. Nr5a2 heterozygosity sensitises to, and cooperates with, inflammation in KRasG12V-driven pancreatic tumourigenesis. Gut 2014, 63(4):647-655.
78. Molero X., Vaquero E.C., Flandez M., et al. Gene expression dynamics after murine pancreatitis unveils novel roles for Hnf1alpha in acinar cell homeostasis. Gut 2012, 61:1187-1196.
79. Landi M.T., Chatterjee N., Yu K., et al. A genome-wide association study of lung cancer identifies a region of chromosome 5p15 associated with risk for adenocarcinoma. Am J Hum Genet 2009, 85:679-691.
80. McKay J.D., Hung R.J., Gaborieau V., et al. Lung cancer susceptibility locus at 5p15.33. Nat Genet 2008, 40:1404-1406.
81. Amos C.I., Wu X., Broderick P., et al. Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1. Nat Genet 2008, 40:616-622.
82. Broderick P., Wang Y., Vijayakrishnan J., et al. Deciphering the impact of common genetic variation on lung cancer risk: a genome-wide association study. Cancer Res 2009, 69:6633-6641.
83. Hsiung C.A., Lan Q., Hong Y.C., et al. The 5p15.33 locus is associated with risk of lung adenocarcinoma in never-smoking females in Asia. PLoS Genet 2010, 6. [pii: e1001051].
84. Kote-Jarai Z., Olama A.A., Giles G.G., et al. Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study. Nat Genet 2011, 43:785-791.
85. Rafnar T., Sulem P., Stacey S.N., et al. Sequence variants at the TERT-CLPTM1L locus associate with many cancer types. Nat Genet 2009, 41:221-227.
86. Chung C.C., Ciampa J., Yeager M., et al. Fine mapping of a region of chromosome 11q13 reveals multiple independent loci associated with risk of prostate cancer. Hum Mol Genet 2011, 20:2869-2878.
87. Shete S., Hosking F.J., Robertson L.B., et al. Genome-wide association study identifies five susceptibility loci for glioma. Nat Genet 2009, 41:899-904.
88. Turnbull C., Rapley E.A., Seal S., et al. Variants near DMRT1, TERT and ATF7IP are associated with testicular germ cell cancer. Nat Genet 2010, 42:604-607.
89. Stacey S.N., Sulem P., Masson G., et al. New common variants affecting susceptibility to basal cell carcinoma. Nat Genet 2009, 41:909-914.
90. Barrett J.H., Iles M.M., Harland M., et al. Genome-wide association study identifies three new melanoma susceptibility loci. Nat Genet 2011, 43:1108-1113.
91. Berndt S.I., Skibola C.F., Joseph V., et al. Genome-wide association study identifies multiple risk loci for chronic lymphocytic leukemia. Nat Genet 2013, 45:868-876.
92. Bodnar A.G., Ouellette M., Frolkis M., et al. Extension of life-span by introduction of telomerase into normal human cells. Science 1998, 279:349-352.
93. Hahn W.C., Counter C.M., Lundberg A.S., et al. Creation of human tumour cells with defined genetic elements. Nature 1999, 400:464-468.
94. Kim N.W., Piatyszek M.A., Prowse K.R., et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994, 266:2011-2015.
95. Ding D., Zhou J., Wang M., et al. Implications of telomere-independent activities of telomerase reverse transcriptase in human cancer. FEBS J 2013, 280:3205-3211.
96. Yamamoto K., Okamoto A., Isonishi S., et al. A novel gene, CRR9, which was up-regulated in CDDP-resistant ovarian tumor cell line, was associated with apoptosis. Biochem Biophys Res Commun 2001, 280:1148-1154.
97. James M.A., Wen W., Wang Y., et al. Functional characterization of CLPTM1L as a lung cancer risk candidate gene in the 5p15.33 locus. PLoS One 2012, 7:e36116.
98. Jia J., Bosley A.D., Thompson A., et al. CLPTM1L promotes growth and enhances aneuploidy in pancreatic cancer cells. Cancer Res 2014, 74(10):2785-2795.
99. Wang Z., Zhu B., Zhang M., et al. Imputation and subset based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33. Hum Mol Genet 2014, 23(24):6616-6633.
100. Bojesen S.E., Pooley K.A., Johnatty S.E., et al. Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet 2013, 45:371-384.
101. Kote-Jarai Z., Saunders E.J., Leongamornlert D.A., et al. Fine-mapping identifies multiple prostate cancer risk loci at 5p15, one of which associates with TERT expression. Hum Mol Genet 2013, 22:2520-2528.
102. McConnell B.B., Yang V.W. Mammalian Kruppel-like factors in health and diseases. Physiol Rev 2010, 90:1337-1381.
103. Dong J.T., Chen C. Essential role of KLF5 transcription factor in cell proliferation and differentiation and its implications for human diseases. Cell Mol Life Sci 2009, 66:2691-2706.
104. Nakamura Y., Migita T., Hosoda F., et al. Kruppel-like factor 12 plays a significant role in poorly differentiated gastric cancer progression. Int J Cancer 2009, 125:1859-1867.
105. Mori A., Moser C., Lang S.A., et al. Up-regulation of Kruppel-like factor 5 in pancreatic cancer is promoted by interleukin-1beta signaling and hypoxia-inducible factor-1alpha. Mol Cancer Res 2009, 7:1390-1398.
106. Stoffers D.A., Zinkin N.T., Stanojevic V., et al. Pancreatic agenesis attributable to a single nucleotide deletion in the human IPF1 gene coding sequence. Nat Genet 1997, 15:106-110.
107. MacDonald R.J., Swift G.H., Real F.X. Transcriptional control of acinar development and homeostasis. Prog Mol Biol Transl Sci 2010, 97:1-40.
108. Vaxillaire M., Bonnefond A., Froguel P. The lessons of early-onset monogenic diabetes for the understanding of diabetes pathogenesis. Best Pract Res Clin Endocrinol Metab 2012, 26:171-187.
109. Ohlsson H., Karlsson K., Edlund T. IPF1, a homeodomain-containing transactivator of the insulin gene. EMBO J 1993, 12:4251-4259.
110. Adams J.C., Seed B., Lawler J. Muskelin, a novel intracellular mediator of cell adhesive and cytoskeletal responses to thrombospondin-1. EMBO J 1998, 17:4964-4974.
111. Fernandez-Zapico M.E., Lomberk G.A., Tsuji S., et al. A functional family-wide screening of SP/KLF proteins identifies a subset of suppressors of KRAS-mediated cell growth. Biochem J 2011, 435:529-537.
112. Small K.S., Hedman A.K., Grundberg E., et al. Identification of an imprinted master trans regulator at the KLF14 locus related to multiple metabolic phenotypes. Nat Genet 2011, 43:561-564.
113. Barrett A., Pellet-Many C., Zachary I.C., et al. p130Cas: a key signalling node in health and disease. Cell Signal 2013, 25:766-777.
114. Cabodi S., del Pilar Camacho-Leal M., Di Stefano P., et al. Integrin signalling adaptors: not only figurants in the cancer story. Nat Rev Cancer 2010, 10:858-870.
115. Whitcomb D.C., Lowe M.E. Human pancreatic digestive enzymes. Dig Dis Sci 2007, 52:1-17.
116. Hao H.X., Xie Y., Zhang Y., et al. ZNRF3 promotes Wnt receptor turnover in an R-spondin-sensitive manner. Nature 2012, 485:195-200.
117. Antoni L., Sodha N., Collins I., et al. CHK2 kinase: cancer susceptibility and cancer therapy - two sides of the same coin?. Nat Rev Cancer 2007, 7:925-936.
118. Gronwald J., Cybulski C., Piesiak W., et al. Cancer risks in first-degree relatives of CHEK2 mutation carriers: effects of mutation type and cancer site in proband. Br J Cancer 2009, 100:1508-1512.
119. Grisanzio C., Freedman M.L. Chromosome 8q24-associated cancers and MYC. Genes Cancer 2010, 1:555-559.
120. Huppi K., Pitt J.J., Wahlberg B.M., et al. The 8q24 gene desert: an oasis of non-coding transcriptional activity. Front Genet 2012, 3:69.
121. Pharoah P.D., Tsai Y.Y., Ramus S.J., et al. GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nat Genet 2013, 45:362-370. 370e1-2.
122. Low S.K., Kuchiba A., Zembutsu H., et al. Genome-wide association study of pancreatic cancer in Japanese population. PLoS One 2010, 5:e11824.
123. Wu C., Miao X., Huang L., et al. Genome-wide association study identifies five loci associated with susceptibility to pancreatic cancer in Chinese populations. Nat Genet 2012, 44:62-66.
124. Campa D., Rizzato C., Bauer A.S., et al. Lack of replication of seven pancreatic cancer susceptibility loci identified in two Asian populations. Cancer Epidemiol Biomarkers Prev 2013, 22:320-323.
125. Glucksmann M.A., Lehto M., Tayber O., et al. Novel mutations and a mutational hotspot in the MODY3 gene. Diabetes 1997, 46:1081-1086.
126. Carette C., Vaury C., Barthelemy A., et al. Exonic duplication of the hepatocyte nuclear factor-1beta gene (transcription factor 2, hepatic) as a cause of maturity onset diabetes of the young type 5. J Clin Endocrinol Metab 2007, 92:2844-2847.
127. Yamagata K., Oda N., Kaisaki P.J., et al. Mutations in the hepatocyte nuclear factor-1alpha gene in maturity-onset diabetes of the young (MODY3). Nature 1996, 384:455-458.
128. Voight B.F., Scott L.J., Steinthorsdottir V., et al. Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. Nat Genet 2010, 42:579-589.
129. Furuta H., Furuta M., Sanke T., et al. Nonsense and missense mutations in the human hepatocyte nuclear factor-1 beta gene (TCF2) and their relation to type 2 diabetes in Japanese. J Clin Endocrinol Metab 2002, 87:3859-3863.
130. Holmkvist J., Cervin C., Lyssenko V., et al. Common variants in HNF-1 alpha and risk of type 2 diabetes. Diabetologia 2006, 49:2882-2891.
131. Garcia-Closas M., Couch F.J., Lindstrom S., et al. Genome-wide association studies identify four ER negative-specific breast cancer risk loci. Nat Genet 2013, 45:392-398. 398e1-2.
132. Al Olama A.A., Kote-Jarai Z., Berndt S.I., et al. A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer. Nat Genet 2014, 46:1103-1109.
133. Wu C., Kraft P., Stolzenberg-Solomon R., et al. Genome-wide association study of survival in patients with pancreatic adenocarcinoma. Gut 2014, 63(1):152-160.
134. Willis J.A., Olson S.H., Orlow I., et al. A replication study and genome-wide scan of single-nucleotide polymorphisms associated with pancreatic cancer risk and overall survival. Clin Cancer Res 2012, 18:3942-3951.
135. Innocenti F., Owzar K., Cox N.L., et al. A genome-wide association study of overall survival in pancreatic cancer patients treated with gemcitabine in CALGB 80303. Clin Cancer Res 2012, 18:577-584.
136. Jones S., Hruban R.H., Kamiyama M., et al. Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science 2009, 324:217.
137. Roberts N.J., Jiao Y., Yu J., et al. ATM mutations in patients with hereditary pancreatic cancer. Cancer Discov 2012, 2:41-46.
138. Marth G.T., Yu F., Indap A.R., et al. The functional spectrum of low-frequency coding variation. Genome Biol 2011, 12:R84.
139. Goldstein A.M., Chan M., Harland M., et al. High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL. Cancer Res 2006, 66:9818-9828.
140. Lynch H.T., Fusaro R.M., Lynch J.F., et al. Pancreatic cancer and the FAMMM syndrome. Fam Cancer 2008, 7:103-112.
141. van Lier M.G., Wagner A., Mathus-Vliegen E.M., et al. High cancer risk in Peutz-Jeghers syndrome: a systematic review and surveillance recommendations. Am J Gastroenterol 2010, 105:1258-1264. [author reply: 1265].
142. Kastrinos F., Mukherjee B., Tayob N., et al. Risk of pancreatic cancer in families with Lynch syndrome. JAMA 2009, 302:1790-1795.
143. Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst 1999, 91:1310-1316. Breast Cancer Linkage Consortium.
144. Lowenfels A.B., Maisonneuve P., DiMagno E.P., et al. Hereditary pancreatitis and the risk of pancreatic cancer. International Hereditary Pancreatitis Study Group. J Natl Cancer Inst 1997, 89:442-446.
145. Howes N., Lerch M.M., Greenhalf W., et al. Clinical and genetic characteristics of hereditary pancreatitis in Europe. Clin Gastroenterol Hepatol 2004, 2:252-261.
146. Witt H., Luck W., Hennies H.C., et al. Mutations in the gene encoding the serine protease inhibitor, Kazal type 1 are associated with chronic pancreatitis. Nat Genet 2000, 25:213-216.
147. Michaud D.S., Wolpin B., Giovannucci E., et al. Prediagnostic plasma C-peptide and pancreatic cancer risk in men and women. Cancer Epidemiol Biomarkers Prev 2007, 16:2101-2109.
148. Stolzenberg-Solomon R.Z., Weinstein S., Pollak M., et al. Prediagnostic adiponectin concentrations and pancreatic cancer risk in male smokers. Am J Epidemiol 2008, 168:1047-1055.
149. Bao Y., Giovannucci E.L., Kraft P., et al. A prospective study of plasma adiponectin and pancreatic cancer risk in five US cohorts. J Natl Cancer Inst 2013, 105:95-103.
150. Stolzenberg-Solomon R.Z., Limburg P., Pollak M., et al. Insulin-like growth factor (IGF)-1, IGF-binding protein-3, and pancreatic cancer in male smokers. Cancer Epidemiol Biomarkers Prev 2004, 13:438-444.
151. Rohrmann S., Grote V.A., Becker S., et al. Concentrations of IGF-I and IGFBP-3 and pancreatic cancer risk in the European Prospective Investigation into Cancer and Nutrition. Br J Cancer 2012, 106:1004-1010.
152. Wolpin B.M., Michaud D.S., Giovannucci E.L., et al. Circulating insulin-like growth factor axis and the risk of pancreatic cancer in four prospective cohorts. Br J Cancer 2007, 97:98-104.
153. Wolpin B.M., Michaud D.S., Giovannucci E.L., et al. Circulating insulin-like growth factor binding protein-1 and the risk of pancreatic cancer. Cancer Res 2007, 67:7923-7928.
154. Grote V.A., Kaaks R., Nieters A., et al. Inflammation marker and risk of pancreatic cancer: a nested case-control study within the EPIC cohort. Br J Cancer 2012, 106:1866-1874.
155. Bao Y., Giovannucci E.L., Kraft P., et al. Inflammatory plasma markers and pancreatic cancer risk: a prospective study of five U.S. cohorts. Cancer Epidemiol Biomarkers Prev 2013, 22:855-861.
156. Jacobs E.J., Newton C.C., Silverman D.T., et al. Serum transforming growth factor-beta1 and risk of pancreatic cancer in three prospective cohort studies. Cancer Causes Control 2014, 25:1083-1091.